Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
Open Access
- 22 August 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (44) , 76479-76491
Abstract
Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cellsKeywords
This publication has 34 references indexed in Scilit:
- 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)The Breast, 2016
- Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast CancerChemotherapy, 2016
- Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysisBreast Cancer Research and Treatment, 2015
- Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapyCancer, 2015
- Taxane-containing regimens for metastatic breast cancerCochrane Database of Systematic Reviews, 2015
- Increased chemoresistance to paclitaxel in the MCF10AT series of human breast epithelial cancer cellsOncology Reports, 2015
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor ModelsClinical Cancer Research, 2013
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast CancerClinical Cancer Research, 2012
- Survivin Modulates Microtubule Dynamics and Nucleation throughout the Cell CycleMolecular Biology of the Cell, 2006
- Oncogenic Mutations of PIK3CA in Human CancersCell Cycle, 2004